About This Study

RENEW-Op-1 is a clinical research study looking at brenipatide, an investigational medication, as an add-on to buprenorphine treatment for people with opioid use disorder (OUD). The study does not ask you to change or stop your current buprenorphine treatment — it's testing whether something added on top of it can offer extra support.

The study is sponsored by Eli Lilly and Company and is being conducted under full Health Canada and Research Ethics Board oversight at our site in Penticton, BC.

Who May Qualify

• You're 18 to 75 years old
• You're currently being treated for opioid use disorder with buprenorphine (with or without naloxone)
• You've had some opioid use since starting your current buprenorphine treatment
• You're willing to try a once-weekly injection (or have a support person help)

This is a short summary, not the complete list. Our team will go over full details with you by phone.

What to Expect

• You leave your contact information below — no health questions on this page.
• A member of our study team calls or emails you, usually within 2 business days.
• We ask some questions by phone to see if the study might be a fit — confidential, no obligation.
• If it looks like a possible match, we book a visit to meet the study doctor and go over everything in detail.

Compensation

Qualified participants receive a stipend for their participation, plus compensation for travel and meals related to study visits.

Prefer to Call or Email Directly?

Medical Arts Health Research Group – Penticton

613 Martin Street, Penticton, BC V2A 5L5
Call: (888) 490-4320 | Email: maria@medicalartsresearch.com